H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:

Phase IIa Investigation of H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06325696
• Other study ID #: 10001577
• Secondary ID: 001577-E
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: May 15, 2024
• Est. completion date: December 31, 2025

Study information

• Verified date: March 19, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: NIEHS Join A Study Recruitment Group
• Phone: (855) 696-4347
• Email: myniehs[@]nih.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: Interstitial lung disease affects the tissues that aid the transfer of oxygen and carbon dioxide between the air and the bloodstream. The disease can cause fibrosis, a thickening and scarring of lung tissue. Fibrosis often continues getting worse, and most people with this disease die in 3 to 5 years. Objective: To test a study drug (hymecromone) in people with interstitial lung disease or lung fibrosis. Eligibility: People aged 18 years and older with interstitial lung disease or lung fibrosis. Design: Participants will have at least 7 clinic visits over 5 months. Participants will have screening and baseline visits. They will have blood tests and tests of their heart function. They will give a sputum sample. Other tests will include: Spirometry: Participants will breathe in and out through a mouthpiece to measure how much air they can hold in their lungs and how hard they can breathe. Diffusion capacity of lungs for carbon monoxide: Participants will breathe in a gas that contains a small amount of carbon monoxide. Then they will breathe through a mouthpiece. This test measures how well oxygen moves from the air into the blood. Resting energy expenditure. Participants will lie still for 30 minutes with a clear dome over their head. This test measures the calories their body burns at rest. 6-minute walk test. Participants will walk at their normal pace for 6 minutes. Their vital signs and blood oxygen levels will be checked. Hymecromone is a tablet taken by mouth. Participants will take 2 tablets every morning and 2 tablets every night for 12 weeks. Tests will be repeated at study visits.

Description:

Study Description: Phase 2a, open-label, study to evaluate the safety, tolerability, and efficacy of H01 in adults with progressive interstitial lung disease. Up to 37 participants will be enrolled. Objectives: Primary Objective: Evaluate the efficacy of H01 in reducing hyaluronan levels in participants with progressive interstitial lung disease. Secondary Objectives: - Evaluate the safety and tolerability of oral H01 in participants with progressive interstitial lung disease. - Evaluate the change in clinical and functional measures in participants with progressive interstitial lung disease treated with H01. - Evaluate biomarkers of fibrosis in participants with progressive interstitial lung disease treated with H01. - Evaluate pharmacokinetic changes from baseline in participants with progressive interstitial lung disease treated with H01 Endpoints: Primary Endpoint: Serum HA levels before and after initiation of treatment with H01 over a period of 12 weeks. Secondary Endpoints: - Safety and tolerability (according to Common Terminology Criteria for Adverse Events) - Change in sputum hyaluronan levels - Change in 6-minute walk test (6MWT) - Change in pulmonary function test (PFT) including: FVC, DLCO - Change in symptom score on Saint George s Respiratory Questionnaire (SGRQ) and King s Brief Interstitial Lung Disease (KBILD) Questionnaire - Change in right ventricular (RV) pressures in echocardiography before treatment and after 12 weeks of H01 treatment - RV Systolic Pressure, Right Atrial Pressure, presence of pericardial effusion, RV size and function via Tricuspid Annular Plane Systolic Excursion /RV Fractional Area Change, Left Ventricular function and Ejection Fraction Exploratory: - Markers of fibrosis (e.g., monocyte count, monocyte/lymphocyte ratio, cytokine analysis (other, e.g., circulating fibrocytes) - Pharmacokinetic changes from baseline to study visits and study follow-up for H01 and active metabolite (4-MU, and 4-MUG)

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 37
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

• INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the

following criteria:

• Ability of subject to understand, and the willingness to sign a written informed consent document and comply with requirements of the study
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Male or Female participants ages >18 years
• MD diagnosis of Idiopathic Pulmonary Fibrosis or other progressive ILD as defined previously
• DLCO>30% <80%, FVC>45% and <80%
• Subjects in reproductive age who are heterosexually active must use an acceptable method of contraception: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, IUD, or Hormone-based contraceptive
• Agreement to adhere to Lifestyle Considerations throughout study duration EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation

in this study:

• Active on lung transplantation list
• On supplemental oxygen at rest
• Evidence of an acute respiratory infection or exacerbation of pulmonary fibrosis at any time during enrollment or study
• Known diagnosis of celiac disease or wheat or gluten allergies
• Cirrhosis or active viral or non-viral hepatitis: Bilirubin, AST and ALT values higher than twice the upper range of normal, or a Child-Pugh score of 7 or more
• Subjects with history of active Inflammatory Bowel Disease, dysphagia, achalasia, or difficulty swallowing capsules, tablets or pills
• Subjects with significant renal impairment defined as eGFR lower than 60 ml/min.
• Subjects with a baseline corrected Fridericia's QT interval (QTcF) >450ms or baseline ECG abnormalities which, in the opinion of the study physician, are clinically significant and would place the participant at increased risk for adverse effects.
• Subjects with ongoing alcohol or illegal drug use disorder
• Subjects who are pregnant, lactating or attempting to conceive
• Participants able to become pregnant (have not completed menopause, had a hysterectomy and/or both tubes and/or both ovaries removed) must use effective birth control methods to try and not become pregnant while participant in this study. Methods include (a) partner vasectomy, (b) bilateral tubal ligation, (c) intrauterine devices (IUDs), (d) hormonal implants (such as Implanon), or (e) other hormonal methods (birth control pills, injections, patches, vaginal rings).
• Male participants able to father children with a partner able to become pregnant must agree to use effective birth control (listed above) to participate in this study.
• Known allergy to hymecromone or any component thereof
• Chronic therapy with medications that are known potent human UDPglucuronosyltransferase inhibitors: canagliflozin, temazepam, tacrolimus.
• Physician concern that participant may not adhere to the study protocol
• Current participation in another clinical treatment trial for ILD. May participate after 12 weeks from conclusion of another treatment trial.
• Changing dose of other ILD medications over the 3 months prior to baseline
• Any condition(s) or diagnosis, both physical or psychological, or physical exam finding that place the participant at increased risk for adverse effects, as determined by the study physician.

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease
• Lung Diseases
• Lung Diseases, Interstitial
• Pulmonary Fibrosis

Intervention

Drug:
• hymecromone
400 mg

Locations

Country	Name	City	State
United States	NIEHS Clinical Research Unit (CRU)	Research Triangle Park	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Environmental Health Sciences (NIEHS)

Country where clinical trial is conducted

United States, 

References & Publications (4)

Garantziotis S, Steele MP, Schwartz DA. Pulmonary fibrosis: thinking outside of the lung. J Clin Invest. 2004 Aug;114(3):319-21. doi: 10.1172/JCI22497. — View Citation

Lederer DJ, Martinez FJ. Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018 Aug 23;379(8):797-798. doi: 10.1056/NEJMc1807508. No abstract available. — View Citation

Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax. 2011 Jun;66(6):462-7. doi: 10.1136/thx.2010.148031. Epub 2011 Apr 27. — View Citation

Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, Collard HR. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014 Jul;2(7):566-72. doi: 10.1016/S2213-2600(14)70101-8. Epub 2014 May 27. Erratum In: Lancet Respir Med. 2014 Jul;2(7):e12. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the efficacy of H01 in reducing serum hyaluronan levels in participants with progressive ILD		Serum HA levels before and after initiation of treatment with H01 over a period of 12 weeks
Secondary	Evaluate the safety and tolerability of oral H01 in participants with progressive ILD.		On-going throughout study; each study visit
Secondary	Evaluate the change in clinical and functional measures in participants with progressive ILD treated with H01.		On-going throughout study; each study visit
Secondary	Evaluate biomarkers of fibrosis in participants with progressive ILD treated with H01.		On-going throughout study; each study visit
Secondary	Evaluate pharmacokinetic changes from baseline in participants with progressive ILD treated with H01.		On-going throughout study; each study visit

External Links

•   NIH Clinical Center Detailed Web Page